Keywords: Roche, RoActemra, Rheumatoid arthritis, Superiority over Humira

Roche's RoActemra shows superiority to Humira in rheumatoid arthritis

Article | 18 March 2013

Print This

Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug major Roche’s (ROG: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in